Product Images Rivaroxaban

This is a description of a medication called Rivaroxaban Tablets, USP, used for the treatment of deep vein thrombosis and pulmonary embolism. The text provides information on dosage instructions for the first 21 days and Day 22 and mentions a Starter Pack for the initial 30-day supply. It also advises to refer to the full Prescribing Information and Medication Guide included. Additionally, the text includes details such as the NDC number, dosing guidelines, and pharmaceutical company information.*

This text contains information about a medication called Rivaroxaban, which is manufactured by Alembic Pharmaceuticals. The recommended storage temperature is 25°C (77°F) with excursions permitted to 15° to 30°C (55° to 86°F). The medication comes in tablet form with a package containing 60 tablets. It is important to keep the medication out of reach of children and to refer to the accompanying Medication Guide. Additionally, the NDC code provided is 62332-683-60.*

This text provides information about a medication called Rivaroxaban in tablet form, with a dosage of 20mg. It includes details about storage conditions, manufacturer information, and a medication guide. The medication is manufactured by Alembic Pharmaceuticals Limited in India and distributed by Alembic Pharmaceuticals, Inc. in the USA. The text also mentions a National Drug Code (NDC) for the product. It is important to keep the medication out of reach of children and dispense the accompanying Medication Guide to each patient. The text includes a contact number for more information and some reference numbers related to the product.*

This is a list of interacting drugs and their effects on PK (pharmacokinetics) indicated by fold change and 90% confidence intervals. The drugs are classified based on their effect on P-gp (P-glycoprotein) and CYP3A enzymes, with categories for combined inhibitors, moderate inhibitors, and strong inducers. Additionally, there is a section for other drugs like Aspirin, Atorvastatin, and Omeprazole, showing their impact on parameters like Cmax (peak plasma concentration) and AUC (area under the concentration-time curve).*

This is a table showing the number of subjects at risk in a treatment group over different days from randomization. The data includes counts for both Rivaroxaban and Placebo groups. This information can be used to analyze the progression and outcomes of the treatment under investigation over the specified time intervals.*

This text provides information on the Cumulative Event Rate (%) for different treatments including Enoxaparin, VKA, and Rivaroxaban Tablets. It also includes the Hazard Ratio (HR) and confidence intervals for comparison between treatments over various days from randomization.*

This text shows a graph depicting the Cumulative Event Rate (%) for different medications over a period of 360 days from randomization. The medications compared include Enoxaparin, VKA, and Rivaroxaban Tablets. The Hazard Ratio (HR) with its corresponding 95% Confidence Interval (CI) is provided as 142 (0.75,1.68). The graph shows how the event rate changes over time for each medication.*

This is a table showing the cumulative event rate (%) for Rivaroxaban tablets and Aspirin over a time period. The Hazard Ratio (95% CI) for Rivaroxaban tablets is 0.26 (0.14-0.47). The number of subjects at risk is also provided for both Rivaroxaban tablets and Aspirin.*